Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
03.06. | Nxera Hits Important Milestone in Diabetes Drug Partnership with Eli Lilly | 9 | Insider Monkey | ||
03.06. | Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 | 110 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 3 June 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that its partner, Neurocrine Biosciences ("Neurocrine") has dosed the first... ► Artikel lesen | |
02.06. | Nxera Pharma Reaches Key Milestone In Lilly Partnership For Diabetes & Metabolic Disease Research | 463 | AFX News | INDIANAPOLIS (dpa-AFX) - Nxera Pharma Co., Ltd. announced that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Co. (LLY)... ► Artikel lesen | |
02.06. | Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases | 129 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 2 June 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration... ► Artikel lesen | |
02.05. | Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025 | 137 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 2 May 2025 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter... ► Artikel lesen | |
01.05. | Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia | 167 | GlobeNewswire (Europe) | NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with NeurocrineFor more information... ► Artikel lesen | |
01.05. | Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations | 1 | GlobeNewswire (USA) | ||
03.04. | Nxera Pharma appoints AstraZeneca alum as inaugural commercial chief | 3 | FiercePharma | ||
NXERA PHARMA Aktie jetzt für 0€ handeln | |||||
01.04. | Nxera Pharma Announces Appointments to its Executive Leadership Team | 1 | GlobeNewswire (USA) | ||
25.03. | Nxera Pharma's Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder | 281 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 25 March 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a... ► Artikel lesen | |
28.02. | Nxera sells APAC license to lupus drug to Viatris for $10M upfront | 32 | FierceBiotech | ||
28.02. | Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan | 1 | GlobeNewswire (USA) | ||
28.02. | Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris | 30 | GlobeNewswire (USA) | ||
14.02. | Nxera Pharma Proposes Changes to its Board of Directors | 1 | GlobeNewswire (USA) | ||
14.02. | Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024 | 350 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) provides an update on operational activities and reports its consolidated results for... ► Artikel lesen | |
07.02. | Singtel's Nxera DCT bags $643m green loan for new data centre in Tuas | 2 | Singapore Business Review | ||
23.01. | Nxera Pharma Webinar Presentation for FY2024 Financial Results | 3 | GlobeNewswire (USA) | ||
14.01. | Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio | 11 | GlobeNewswire (USA) | ||
19.12.24 | Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Adults with Insomnia | 14 | GlobeNewswire (USA) | ||
05.12.24 | Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea | 184 | GlobeNewswire (Europe) | Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomniaQUVIVIQ (daridorexant) 25 and 50 mg was recently approved and is expected... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 21,190 | -0,21 % | Massive Veränderung voraus? Hims & Hers Health, Novartis, PanGenomic Health, Pfizer | Mit einem Paukenschlag wartete Anfang der Woche der US-Gesundheitsminister Robert Kennedy auf. Der Kritiker an dem massiven Anstieg der Impfhäufigkeit in den letzten 40 Jahren in den USA gab bekannt... ► Artikel lesen | |
NOVARTIS | 103,02 | -0,39 % | Schock-News für Morphosys Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
GILEAD SCIENCES | 95,00 | -0,24 % | Dividendenbekanntmachungen (13.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 2G ENERGY AG DE000A0HL8N9 - 0,2 EUR ADANI PORTS AND SPECIAL ECONOMIC ZONE LT ... INE742F01042 7 INR 0,0705 EUR ALBEMARLE CORPORATION US0126531013 0... ► Artikel lesen | |
SANOFI | 85,99 | -0,03 % | Sanofi SA-Aktie: Kurs fällt ab (87,82 €) | Im Minus liegt aktuell das Wertpapier von Sanofi SA . Die Aktie kostete zuletzt 87,82 Euro. Die Aktie von Sanofi SA verzeichnet derzeit einen Kursrückgang von 1,44 Prozent. Sie hat sich um 1,28 Euro... ► Artikel lesen | |
ABBVIE | 165,40 | -0,12 % | U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus | MAVYRET® (glecaprevir/pibrentasvir) is the first and only oral eight-week pangenotypic treatment option approved for people with acute or chronic hepatitis C virus... ► Artikel lesen | |
ROCHE | 285,00 | +0,07 % | Roche-CEO: Trumps Arznei-Preis-Dekret bedroht US-Investitionen | DJ Roche-CEO: Trumps Arznei-Preis-Dekret bedroht US-Investitionen
Von Jared S. Hopkins
DOW JONES--US-Präsident Trump könnte nach Einschätzung eines hochrangigen Pharmamanagers mit seinem Dekret... ► Artikel lesen | |
ABBOTT LABORATORIES | 118,38 | +0,56 % | Abbott Declares 406th Consecutive Quarterly Dividend | ABBOTT PARK, Ill., June 13, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share.
This... ► Artikel lesen | |
HAEMATO | 10,500 | -4,55 % | M1 Kliniken: Verkauf von HAEMATO PHARM im Fokus | Die M1 Kliniken AG steht vor dem möglichen Verkauf eines Teils der Konzern-Aktivitäten: Die zur Gruppe gehörende HAEMATO AG prüft derzeit ein verbindliches Angebot für den Verkauf ihrer Tochtergesellschaft... ► Artikel lesen | |
INCYTE | 59,32 | +1,13 % | Phase-3-Daten für Retifanlimab (Zynyz) von Incyte bei Patienten mit Plattenepithel-Analkarzinom (SCAC) werden in The Lancet veröffentlicht | POD1UM-303/InterAACT 2 ist die erste und größte globale Phase-3-Studie zur Bewertung eines PD-1-Inhibitors in Kombination mit einer Chemotherapie zur Behandlung von Patienten mit fortgeschrittenem... ► Artikel lesen | |
EDWARDS LIFESCIENCES | 65,45 | +0,60 % | Kurs der Edwards Lifesciences-Aktie verharrt auf Vortags-Niveau (66,0969 €) | An der US-amerikanischen Börse ist die Aktie von Edwards Lifesciences derzeit unauffällig. Die Aktie notiert gegenwärtig bei 75,94 US-Dollar. Kaum auffällig ist zur Stunde am Aktienmarkt der Kurs von... ► Artikel lesen | |
WPD PHARMACEUTICALS | 0,002 | 0,00 % | CSE Bulletin: Consolidation - WPD Pharmaceuticals Inc. (WBIO) | le 23 décembre/December 2024
WPD Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty-five... ► Artikel lesen | |
HALEON | 4,707 | -1,05 % | Haleon plc - 6-K, Report of foreign issuer | ||
BIONANO GENOMICS | 3,650 | -0,82 % | Bionano Genomics, Inc. - 8-K, Current Report | ||
TONIX PHARMACEUTICALS | 27,800 | +0,72 % | Pre-market Movers: Creative Global Technology, Liminatus Pharma, CureVac, Jupiter Neurosciences, Tonix Pharmaceuticals | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.05 A.M. ET).In the Green Creative Global Technology Holdings Limited (CGTL)... ► Artikel lesen | |
GRIFOLS | 10,045 | +0,30 % | XL-protein GmbH: XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation(R) technology | Press Release: XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation(R) technology
Freising, Germany, June 10, 2025 -- XL-protein GmbH, a pioneer in... ► Artikel lesen |